Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.

Detalhes bibliográficos
Autor(a) principal: Diniz, M J
Data de Publicação: 1992
Outros Autores: Dias Francisco, F, Tavares, M L, Leal, I
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230
Resumo: Factor VIII inhibitors arise in 5% to 15% of patients with hemophilia A in response to infusion to factor VIII concentrates and make the treatment of bleeding episodes extremely difficult. Various therapeutic approaches have been tried the decision depending on the type of haemorrhage, the antibody's titre and whether the patient has a low or high response. We report the clinical experience in 13 hemophiliacs with inhibitors to factor VIII. Prothrombin complex concentrates were administered with favorable effects in the most common haemorrhagic episodes, in the majority of patients. In two patients activated prothrombin complex concentrates were administered and in one case plasma exchange was made before high doses of factor VIII. These therapeutic approaches proved to be very effective in the control of hemostasis.
id RCAP_a50e9e72e26e47c655e0f4f3f37769d5
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/3230
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str
spelling Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.Hemofílicos com inibidor. Experiência do Centro de Acção Médica de Hemofilia do Hospital de S. José.Factor VIII inhibitors arise in 5% to 15% of patients with hemophilia A in response to infusion to factor VIII concentrates and make the treatment of bleeding episodes extremely difficult. Various therapeutic approaches have been tried the decision depending on the type of haemorrhage, the antibody's titre and whether the patient has a low or high response. We report the clinical experience in 13 hemophiliacs with inhibitors to factor VIII. Prothrombin complex concentrates were administered with favorable effects in the most common haemorrhagic episodes, in the majority of patients. In two patients activated prothrombin complex concentrates were administered and in one case plasma exchange was made before high doses of factor VIII. These therapeutic approaches proved to be very effective in the control of hemostasis.Factor VIII inhibitors arise in 5% to 15% of patients with hemophilia A in response to infusion to factor VIII concentrates and make the treatment of bleeding episodes extremely difficult. Various therapeutic approaches have been tried the decision depending on the type of haemorrhage, the antibody's titre and whether the patient has a low or high response. We report the clinical experience in 13 hemophiliacs with inhibitors to factor VIII. Prothrombin complex concentrates were administered with favorable effects in the most common haemorrhagic episodes, in the majority of patients. In two patients activated prothrombin complex concentrates were administered and in one case plasma exchange was made before high doses of factor VIII. These therapeutic approaches proved to be very effective in the control of hemostasis.Ordem dos Médicos1992-04-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230oai:ojs.www.actamedicaportuguesa.com:article/3230Acta Médica Portuguesa; Vol. 5 No. 4 (1992): Abril; 178-80Acta Médica Portuguesa; Vol. 5 N.º 4 (1992): Abril; 178-801646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230/2569Diniz, M JDias Francisco, FTavares, M LLeal, Iinfo:eu-repo/semantics/openAccess2022-12-20T11:01:56ZPortal AgregadorONG
dc.title.none.fl_str_mv Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
Hemofílicos com inibidor. Experiência do Centro de Acção Médica de Hemofilia do Hospital de S. José.
title Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
spellingShingle Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
Diniz, M J
title_short Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
title_full Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
title_fullStr Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
title_full_unstemmed Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
title_sort Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital.
author Diniz, M J
author_facet Diniz, M J
Dias Francisco, F
Tavares, M L
Leal, I
author_role author
author2 Dias Francisco, F
Tavares, M L
Leal, I
author2_role author
author
author
dc.contributor.author.fl_str_mv Diniz, M J
Dias Francisco, F
Tavares, M L
Leal, I
description Factor VIII inhibitors arise in 5% to 15% of patients with hemophilia A in response to infusion to factor VIII concentrates and make the treatment of bleeding episodes extremely difficult. Various therapeutic approaches have been tried the decision depending on the type of haemorrhage, the antibody's titre and whether the patient has a low or high response. We report the clinical experience in 13 hemophiliacs with inhibitors to factor VIII. Prothrombin complex concentrates were administered with favorable effects in the most common haemorrhagic episodes, in the majority of patients. In two patients activated prothrombin complex concentrates were administered and in one case plasma exchange was made before high doses of factor VIII. These therapeutic approaches proved to be very effective in the control of hemostasis.
publishDate 1992
dc.date.none.fl_str_mv 1992-04-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230
oai:ojs.www.actamedicaportuguesa.com:article/3230
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/3230
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3230/2569
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 5 No. 4 (1992): Abril; 178-80
Acta Médica Portuguesa; Vol. 5 N.º 4 (1992): Abril; 178-80
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1777301640005550080